Peer Case Review by Specialist Oncologists
Independent, evidence-based evaluation of complex oncology cases by 2-3 board-certified specialist oncologists from our partner network. Reduce individual bias. Access collective expertise. Receive treatment recommendations with PubMed citations and clinical trial matching within 48-72 hours.
A Candid Note for Referring Oncologists
Myth: "Peer review platforms simply rubber-stamp cases and push patients to partner hospitals for commission."
Reality: Our peer reviewers are independent — they have no financial relationship with the receiving institution. In 30% of cases, our reviewers recommend continuing local standard of care rather than international referral. Every recommendation includes PubMed citations so you can verify the evidence yourself. You retain full clinical authority, and we publish our institutional revenue sources on our Financial Transparency page. If your patient doesn't need to travel, we will say so in writing.
Peer Review vs Traditional Second Opinion
Understanding the critical differences that impact clinical decision-making.
Traditional Second Opinion
- Single physician opinion
- Individual bias possible
- Variable response time
- Limited to one specialist's experience
- Often lacks literature citations
- No clinical trial assessment
- Typically $500-$2,000
CancerCareE Peer Review
- 2-3 independent specialist opinions
- Reduced bias through consensus
- 48-72 hour guaranteed response
- Collective expertise from multiple centers
- Evidence-based with PubMed citations
- Clinical trial eligibility assessment
- Completely free for referring physicians
The Peer Review Process
A structured, transparent workflow from submission to final report.
Case Submission
Submit de-identified patient records through our secure HIPAA-aligned portal. Required: pathology reports, imaging studies, treatment history with regimens and response, current performance status (ECOG), molecular markers when available, and specific clinical questions.
15-30 minutes to completeReviewer Assignment
Our medical director reviews the submission and assigns 2-3 specialist oncologists with subspecialty expertise matching the case. Reviewers are selected based on cancer type, prior treatments, and geographic considerations.
Within 4 hoursIndependent Evaluation
Each reviewer independently evaluates the case based on published clinical evidence, NCCN/ESMO/ASCO guidelines, and their clinical expertise. Reviewers do not communicate during this phase to ensure independent assessments.
24-48 hoursConsensus Synthesis
Our medical director synthesizes the independent reviews into a comprehensive consensus report highlighting: areas of agreement, divergent opinions (with reasoning), evidence-based recommendations with literature citations, and clinical trial options across our 8-country network.
48-72 hours totalReport Delivery & Follow-up
Receive the detailed peer review report via secure encrypted email. Optional: Schedule a physician-to-physician consultation call with one or more reviewers to discuss findings and next steps.
Immediate delivery + ongoing supportWhat We Evaluate
Comprehensive assessment covering all critical aspects of the case.
Diagnostic Accuracy
- Pathology review and confirmation
- Staging accuracy assessment (AJCC 8th edition)
- Molecular and genetic marker evaluation
- Imaging interpretation review
- Missing diagnostic workup identification
Treatment Appropriateness
- Previous regimen adequacy assessment
- Dose intensity and schedule review
- Response assessment accuracy (RECIST 1.1 / Lugano)
- Alternative regimen options
- Guideline concordance (NCCN/ESMO/ASCO)
Clinical Trial Eligibility
- Eligibility for 700+ CAR-T trials
- Solid tumor trial matching
- Inclusion/exclusion criteria review
- Trial availability by region (8 countries)
- Next-generation therapy options
Risk-Benefit Analysis
- Treatment toxicity assessment
- Quality of life considerations
- Performance status impact
- Comorbidity interactions
- Patient preference alignment
Prognostic Assessment
- Expected treatment outcomes
- Survival estimates based on evidence
- Response rate predictions
- Progression-free survival data
- Relapse risk stratification
Next Steps Recommendations
- Immediate action items
- Additional diagnostic tests needed
- Referral to subspecialists
- Palliative care integration
- Follow-up schedule and monitoring
How Reviewers Are Selected
Rigorous criteria ensure the highest quality peer review.
Board Certification
All reviewers are board-certified in their subspecialty with active, unrestricted medical licenses.
Subspecialty Match
Reviewers are matched to cases based on cancer type expertise and treatment modality experience.
Geographic Diversity
Reviewers from multiple countries provide diverse perspectives on treatment availability and access.
Academic Credentials
Most reviewers hold academic appointments, have published peer-reviewed research, and participate in clinical trials.
Independence Guarantee
Reviewers have no financial relationship with referring physicians or patients. Reviews are conducted independently.
Continuous Training
Reviewers participate in regular CME and are updated on new approvals, guidelines, and emerging evidence.
Sample Peer Review Report
What you receive after the review process is complete.
Peer Case Review Report
Case ID: PCR-2026-0847 | Submitted: June 5, 2026 | Completed: June 7, 2026 | Review Type: Multi-Specialist Consensus
Reviewer Panel
Reviewer 1: Dr. [Name], MD, PhD - Hematologic Oncology Specialist, [Institution], China
Reviewer 2: Dr. [Name], MD - Medical Oncologist, [Institution], South Korea
Reviewer 3: Dr. [Name], MD - Clinical Trials Expert, [Institution], USA
Areas of Consensus
- All reviewers agree the patient is an appropriate candidate for BCMA-targeted CAR-T therapy
- Previous treatment with lenalidomide and proteasome inhibitors was appropriate per NCCN guidelines
- Performance status (ECOG 1) is adequate for cellular therapy
- Urgent treatment initiation recommended given disease progression
Divergent Opinions
Reviewer 1 recommends proceeding with approved CAR-T product (cilta-cel) based on CARTITUDE-4 trial data (PMID: 35855897), citing established safety profile and regulatory approval.
Reviewer 2 suggests considering clinical trial with next-generation dual-target CAR-T (BCMA/GPRC5D) due to high-risk cytogenetics and potential for improved durability.
Reviewer 3 notes both options are reasonable and provides comparative efficacy data, recommending shared decision-making with patient.
Supporting Evidence
- CARTITUDE-4 Trial: PMID 35855897 - 83% ORR, 76% CR in lenalidomide-refractory MM
- KarMMa-3 Trial: PMID 37232881 - 71% ORR with ide-cel in triple-class exposed MM
- NCCN Guidelines v3.2026: CAR-T recommended for ≥2 prior lines of therapy (Category 1)
- ESMO 2025 Guidelines: BCMA-targeted CAR-T preferred in relapsed/refractory MM
Clinical Trial Options
- Trial 1: NCT05469893 - GPRC5D-targeted CAR-T, Phase 2, China, Recruiting
- Trial 2: NCT05372354 - Dual-target CAR-T (BCMA/GPRC5D), Phase 1/2, USA, Recruiting
- Trial 3: NCT04133636 - Next-gen CAR-T with enhanced persistence, Phase 2, South Korea, Recruiting
Recommended Next Steps
- Obtain updated bone marrow biopsy with flow cytometry and FISH for current disease status
- Complete cardiac evaluation (echocardiogram, BNP) for CAR-T eligibility
- Discuss both approved therapy and clinical trial options with patient
- If proceeding with CAR-T, initiate referral to nearest certified treatment center
Ethics & Confidentiality Standards
Our commitment to patient privacy and professional ethics.
Patient De-identification
All cases are reviewed using de-identified data. No personally identifiable information or protected health information is shared with reviewers without explicit written consent.
HIPAA-Aligned Security
End-to-end encryption for all data transmission. Role-based access controls ensure only assigned reviewers can access case materials. Complete audit trails maintained.
Conflict of Interest Disclosure
All reviewers must disclose potential conflicts before accepting a case. Reviewers with financial relationships to specific products are excluded from relevant cases.
Physician Autonomy Respected
Peer review recommendations are advisory only. The referring physician retains full clinical autonomy. We never interfere with the physician-patient relationship.
Confidentiality Agreements
All reviewers sign comprehensive confidentiality agreements. Case details cannot be disclosed outside the review process. Breaches result in immediate removal from the network.
Evidence-Based Only
Recommendations are based solely on published clinical evidence, established guidelines (NCCN/ESMO/ASCO), and reviewer expertise. No commercial factors influence the review.
Frequently Asked Questions
Common questions about our peer review process.
Peer case review is an evidence-based evaluation of complex oncology cases by 2-3 specialist oncologists who provide independent treatment recommendations based on published clinical evidence, NCCN/ESMO/ASCO guidelines, and their clinical expertise.
Unlike a traditional second opinion from a single physician, our peer review involves multiple specialists providing independent assessments. This reduces individual bias and provides a more comprehensive evaluation with PubMed citations and clinical trial matching.
We require de-identified pathology reports, imaging studies (CT, MRI, PET), treatment history including regimens and response, current performance status (ECOG), molecular/genetic markers when available, and specific clinical questions.
Standard peer review is completed within 48-72 hours of receiving complete clinical documentation. Urgent cases can be expedited within 24 hours upon request.
Yes. Peer case review is completely free for licensed oncologists. Our platform is sustained through institutional partnerships with hospitals, not physician fees.
The report includes: independent assessments from each reviewer, areas of consensus and divergent opinions, evidence-based recommendations with PubMed citations, clinical trial eligibility assessment, risk-benefit analysis, prognostic assessment, and suggested next steps.
Reviewers are board-certified oncologists and hematologists from our partner institutions across 8 countries, with subspecialty expertise matching the case. All reviewers hold active medical licenses.
Yes. After receiving the report, you can schedule a physician-to-physician consultation call with one or more reviewers to discuss the findings in detail. This is included at no additional cost.
Divergent opinions are valuable and expected in complex cases. The report clearly identifies areas of consensus and disagreement, providing you with multiple perspectives to inform your clinical decision-making.
We use HIPAA-aligned security protocols including end-to-end encryption, de-identification of patient data, secure document upload, role-based access controls, and complete audit trails.
Continue Your Clinical Research
Essential resources for physicians evaluating international oncology pathways.
📤 Refer a Patient
Submit a case for peer review or international referral.
Submit case →💰 Financial Transparency
How we are funded — $0 physician fees, institutional model.
View transparency →⚖️ Legal Framework
Our role, liability boundaries, and physician protections.
Read legal →📊 Response Rates
Evidence-based treatment outcomes across therapies.
View data →Ready to Submit a Case for Peer Review?
Get evidence-based recommendations from 2-3 specialist oncologists within 48-72 hours. Free for licensed physicians.
HIPAA-aligned • Free for physicians • 48-72h response • PubMed-cited recommendations